Oncology

Pharmacogenomic testing for DPYD polymorphisms prior to fluoropyrimidine chemotherapy

February 2021 | By Martin Bradley

In November 2020, NHS England issued an urgent policy statement confirming the routine commissioning of pharmacogenomic testing prior to the initiation of fluoropyrimidine chemotherapy.1 This […]

Systemic anticancer treatments during COVID-19 and beyond

February 2021 | By Alastair Whitington

The UK Chemotherapy Board Annual Conference 2020 was held on 26 November 2020 as a virtual event. In this quarter’s Oncology Corner column, Alastair Whitington, […]

Draft guidance approves niraparib for ovarian cancer

February 2021

NICE has published its final appraisal document on niraparib for maintenance treatment of advanced ovarian, fallopian tube, and peritoneal cancer. According to the draft guidance, […]

Proton beam therapy: a new radiotherapy paradigm

December 2020 | By Roger Taylor and Melanie Kay

Radiotherapy is an important curative component of treatment for nearly half of all patients with cancer.1 Proton beam therapy (PBT) is a specialised form of […]

Restarting cancer services will require stratification and coordination

December 2020 | By Nina Buchan

As part of the Virtual UK Oncology Forum 2020, The Big COVID/Cancer Debate took place online on 25 September 2020. This fringe meeting, which was […]

Interview: Professor David Cunningham

December 2020 | By Alastair Whitington

In this short video, Professor David Cunningham, Consultant Medical Oncologist at the The Royal Marsden NHS Foundation Trust and Chair of the Association of Cancer […]

Articles